High dose calcium channel blockers are useful in only 5% of IPAH patients who are "vasoreactive" by Swan-Ganz catheter. Unfortunately, calcium channel blockers have been largely misused, being prescribed to many patients with non-vasoreactive PAH, leading to excess morbidity and mortality.